Phase II trial of etoposide and cisplatin in patients with refractory and relapsed non-Hodgkin's lymphoma: Cancer and leukemia group B study 8351

✍ Scribed by Rybak, Mary Ellen ;Anderson, James ;Kaplan, Richard ;Budman, Daniel R. ;Vinciguerra, Vincent ;Gottlieb, Arlan J.

• Publisher: John Wiley and Sons
• Year: 1993
• Tongue: English
• Weight: 435 KB
• Volume: 21
• Category: Article
• ISSN: 0098-1532
• DOI: 10.1002/mpo.2950210610

✦ Synopsis

Abstract

A phase‐II study was conducted by the Cancer and Leukemia Group B (CALGB) in patients with refractory and relapsed non‐Hodgkin's lymphoma (NHL) to assess the activity of the combination of etoposide and cisplatin. Sixty‐five patients were entered on study, and 51 patients were evaluated for this report. The treatment regimen consisted of etoposide, 80 mg/m^2^ IV daily times 5 and cisplatin 20 mg/m^2^ IV daily times 5, repeated every 21 days. All patients had failed 1–3 prior chemotherapeutic regimens, had measurable disease, and had a performance status of 0–2. In the 51 evaluable patients, there were 4 complete responses (8%) and 12 partial responses (23%), for an overall response rate of 31% (95% Cl: 19%, 46%). In addition, 15 patients (29%) had some improvement in disease and 6 (12%) had stable disease. Failure‐free survival for the 51 eligible patients was 40% at 3 months, 23% at 6 months, and 15% at 1 year. Significant toxicity was observed with this regimen. Severe neutropenia occurred in 20 patients (39%), severe anemia in 8 patients (16%), and severe thrombocytopenia in 18 patients (35%). One patient died of infection. Severe neurotoxicity (1) and hemorrhage (3) were also seen.

The etoposide, cisplatin combination is active in NHL; however, in this dose and schedule their combined activity is only minimally better than published reports of etoposide alone. Further studies of related combinations are under evaluation by the CALGB. © 1993 Wiley‐Liss, Inc.